Literature DB >> 26244146

Targeted drug combinations: avant-garde oncology.

Tu D Dan1, Joshua D Palmer1.   

Abstract

Year:  2015        PMID: 26244146      PMCID: PMC4499666          DOI: 10.3978/j.issn.2305-5839.2015.06.17

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  3 in total

1.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean-Jacques Grob; Vanna Chiarion-Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Suzanne Swann; Jeffrey J Legos; Fan Jin; Bijoyesh Mookerjee; Keith Flaherty
Journal:  Lancet       Date:  2015-05-31       Impact factor: 79.321

2.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

3.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.